Hadron Therapy Market

Executive Summary

Hadron Therapy Market was valued at US $501.40 million in 2021 and is projected to grow at 14.39% CAGR over the forecast period to reach US $1,123.21 million by 2027. Hadron Therapy Market represented US $118.20 million opportunity over 2019-2021 and estimated to create US $621.81 million opportunity in 2027 over 2021.

Hadron Therapy from Consainsights analyses the Hadron Therapy Market in the Life Sciences industry over the forecast period to 2027.

Hadron Therapy research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Hadron Therapy segmentation includes Type, Application, End Use and Geography.

Based on the Type, the Hadron Therapy analysis covers ELECTRON BEAM, PROTON BEAM, NEUTRON BEAM, CARBON ION BEAM, ALPHA PARTICLE BEAM, BETA PARTICLE BEAM.

In Type segment, ELECTRON BEAM segment has highest cagr growth of 12.69%.

Based on the Application, the Hadron Therapy analysis covers PEDIATRIC CANCER, BONE AND SOFT TISSUE CANCER, PROSTATE CANCER, LUNG CANCER, LIVER CANCER, EYE CANCER, HEAD AND NECK CANCER, OTHER APPLICATIONS.

In Application segment, PEDIATRIC CANCER segment has highest cagr growth of 12.69%.

Based on the End Use, the Hadron Therapy analysis covers HOSPITALS, CANCER RESEARCH CENTRES, CLINICS.

In End Use segment, HOSPITALS segment has highest cagr growth of 12.69%.

Based on the region, the Hadron Therapy analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include KONINKLIJKE PHILIPS N.V., ADVANCED ONCOTHERAPY, VARIAN MEDICAL SYSTEMS, INC., OPTIVUS PROTON THERAPY, INC., HITACHI, LTD., MEVION MEDICAL SYSTEMS, PROTOM INTERNATIONAL, MITSUBISHI ELECTRIC CORPORATION, SUMITOMO CORPORATION, PRONOVA SOLUTIONS, LLC and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Type

Introduction

In 2021, ELECTRON BEAM segment has the highest revenue of US $204.46 million and is expected to grow at CAGR of 12.69% by 2027 ELECTRON BEAM segment has highest cagr growth of 12.69%.

ELECTRON BEAM

ELECTRON BEAM segment was valued at US $156.26 million in 2019 and is projected to grow at 12.69% CAGR over the forecast period to reach US $458.02 million by 2027. ELECTRON BEAM segment represented US $48.20 million opportunity over 2019-2021 and estimated to create US $253.56 million opportunity in 2027 over 2021.

PROTON BEAM

PROTON BEAM segment was valued at US $102.88 million in 2019 and is projected to grow at 12.69% CAGR over the forecast period to reach US $301.57 million by 2027. PROTON BEAM segment represented US $31.74 million opportunity over 2019-2021 and estimated to create US $166.95 million opportunity in 2027 over 2021.

NEUTRON BEAM

NEUTRON BEAM segment was valued at US $57.36 million in 2019 and is projected to grow at 12.69% CAGR over the forecast period to reach US $168.12 million by 2027. NEUTRON BEAM segment represented US $17.69 million opportunity over 2019-2021 and estimated to create US $93.07 million opportunity in 2027 over 2021.

CARBON ION BEAM

CARBON ION BEAM segment was valued at US $30.61 million in 2019 and is projected to grow at 12.69% CAGR over the forecast period to reach US $89.73 million by 2027. CARBON ION BEAM segment represented US $9.44 million opportunity over 2019-2021 and estimated to create US $49.68 million opportunity in 2027 over 2021.

ALPHA PARTICLE BEAM

ALPHA PARTICLE BEAM segment was valued at US $12.95 million in 2019 and is projected to grow at 12.69% CAGR over the forecast period to reach US $37.95 million by 2027. ALPHA PARTICLE BEAM segment represented US $3.99 million opportunity over 2019-2021 and estimated to create US $21.01 million opportunity in 2027 over 2021.

BETA PARTICLE BEAM

BETA PARTICLE BEAM segment was valued at US $23.14 million in 2019 and is projected to grow at 12.69% CAGR over the forecast period to reach US $67.82 million by 2027. BETA PARTICLE BEAM segment represented US $7.14 million opportunity over 2019-2021 and estimated to create US $37.55 million opportunity in 2027 over 2021.

Application

Introduction

In 2021, PEDIATRIC CANCER segment has the highest revenue of US $195.14 million and is expected to grow at CAGR of 12.69% by 2027 PEDIATRIC CANCER segment has highest cagr growth of 12.69%.

PEDIATRIC CANCER

PEDIATRIC CANCER segment was valued at US $149.14 million in 2019 and is projected to grow at 12.69% CAGR over the forecast period to reach US $437.15 million by 2027. PEDIATRIC CANCER segment represented US $46.00 million opportunity over 2019-2021 and estimated to create US $242.01 million opportunity in 2027 over 2021.

BONE AND SOFT TISSUE CANCER

BONE AND SOFT TISSUE CANCER segment was valued at US $90.63 million in 2019 and is projected to grow at 12.69% CAGR over the forecast period to reach US $265.65 million by 2027. BONE AND SOFT TISSUE CANCER segment represented US $27.96 million opportunity over 2019-2021 and estimated to create US $147.06 million opportunity in 2027 over 2021.

PROSTATE CANCER

PROSTATE CANCER segment was valued at US $53.67 million in 2019 and is projected to grow at 12.69% CAGR over the forecast period to reach US $157.32 million by 2027. PROSTATE CANCER segment represented US $16.56 million opportunity over 2019-2021 and estimated to create US $87.09 million opportunity in 2027 over 2021.

LUNG CANCER

LUNG CANCER segment was valued at US $36.49 million in 2019 and is projected to grow at 12.69% CAGR over the forecast period to reach US $106.95 million by 2027. LUNG CANCER segment represented US $11.26 million opportunity over 2019-2021 and estimated to create US $59.21 million opportunity in 2027 over 2021.

LIVER CANCER

LIVER CANCER segment was valued at US $24.98 million in 2019 and is projected to grow at 12.69% CAGR over the forecast period to reach US $73.23 million by 2027. LIVER CANCER segment represented US $7.71 million opportunity over 2019-2021 and estimated to create US $40.54 million opportunity in 2027 over 2021.

EYE CANCER

EYE CANCER segment was valued at US $16.74 million in 2019 and is projected to grow at 12.69% CAGR over the forecast period to reach US $49.07 million by 2027. EYE CANCER segment represented US $5.16 million opportunity over 2019-2021 and estimated to create US $27.17 million opportunity in 2027 over 2021.

HEAD AND NECK CANCER

HEAD AND NECK CANCER segment was valued at US $9.88 million in 2019 and is projected to grow at 12.69% CAGR over the forecast period to reach US $28.96 million by 2027. HEAD AND NECK CANCER segment represented US $3.05 million opportunity over 2019-2021 and estimated to create US $16.03 million opportunity in 2027 over 2021.

OTHER APPLICATIONS

OTHER APPLICATIONS segment was valued at US $1.66 million in 2019 and is projected to grow at 12.69% CAGR over the forecast period to reach US $4.88 million by 2027. OTHER APPLICATIONS segment represented US $0.51 million opportunity over 2019-2021 and estimated to create US $2.70 million opportunity in 2027 over 2021.

End Use

Introduction

In 2021, HOSPITALS segment has the highest revenue of US $210.15 million and is expected to grow at CAGR of 12.69% by 2027 HOSPITALS segment has highest cagr growth of 12.69%.

HOSPITALS

HOSPITALS segment was valued at US $160.61 million in 2019 and is projected to grow at 12.69% CAGR over the forecast period to reach US $470.77 million by 2027. HOSPITALS segment represented US $49.54 million opportunity over 2019-2021 and estimated to create US $260.62 million opportunity in 2027 over 2021.

CANCER RESEARCH CENTRES

CANCER RESEARCH CENTRES segment was valued at US $119.71 million in 2019 and is projected to grow at 12.69% CAGR over the forecast period to reach US $350.88 million by 2027. CANCER RESEARCH CENTRES segment represented US $36.92 million opportunity over 2019-2021 and estimated to create US $194.25 million opportunity in 2027 over 2021.

CLINICS

CLINICS segment was valued at US $102.88 million in 2019 and is projected to grow at 12.69% CAGR over the forecast period to reach US $301.55 million by 2027. CLINICS segment represented US $31.73 million opportunity over 2019-2021 and estimated to create US $166.94 million opportunity in 2027 over 2021.